MedTrace Logo

Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy

NCT00189683 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2005-09-19

No results posted yet for this study

Summary

To compare maintenance chemotherapy with Xeloda to control after best response with first line chemotherapy in advanced colorectal cancer. Main endpoint is progression free survival. A total of 300 patients will be included.

Conditions

Interventions

PROCEDURE

Monitoring

PROCEDURE

Xeloda

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Association Européenne de Recherche en Oncologie

    lead OTHER

Principal Investigators

  • Elizabeth Fabre-Guillevin, MD · AERO

  • Eric Van Cutsem, MD · BGDO

  • Marc Polus, MD · BGDO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00189683 on ClinicalTrials.gov